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Abstract
Here we show that bortezomib induces effective proteasome inhibition and accumulation of poly-ubiquitinated proteins in
diffuse large B-cell lymphoma (DLBCL) cells. This leads to induction of endoplasmic reticulum (ER) stress as demonstrated by
accumulation of the protein CHOP, as well as autophagy, as demonstrated by accumulation of LC3-II proteins. Our data
suggest that recruitment of both ubiquitinated proteins and LC3-II by p62 directs ubiquitinated proteins, including I-kBa,t o
the autophagosome. Degradation of I-kBa results in increased NF-kB nuclear translocation and transcription activity. Since
bortezomib treatment promoted I-kBa phosphorylation, ubiquitination and degradation, this suggests that the route of I-
kBa degradation was not via the ubiquitin-proteasome degradation system. The autophagy inhibitor chloroquine (CQ)
significantly inhibited bortezomib-induced I-kBa degradation, increased complex formation with NF-kB and reduced NF-kB
nuclear translocation and DNA binding activity. Importantly, the combination of proteasome and autophagy inhibitors
showed synergy in killing DLBCL cells. In summary, bortezomib-induced autophagy confers relative DLBCL cell drug
resistance by eliminating I-kBa. Inhibition of both autophagy and the proteasome has great potential to kill apoptosis-
resistant lymphoma cells.
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Introduction
The proteasome inhibitor, bortezomib, is a novel anti-cancer
drug and has been administrated successfully to treat relapsed/
refractory multiple myeloma [1,2]. Previous studies have suggested
that proteasome inhibition by bortezomib kills cancer cells via
blocking inducible I-kBa degradation and subsequently NF-kB
activation [3,4,5], or preventing protein degradation of pro-
apoptotic proteins such as Bax or p53 [6,7]. However, it was
recently reported that bortezomib-induced accumulation of poly-
ubiquitinated proteins leads to formation of aggresomes which
minimize their ‘proteotoxicity’ allowing these toxic proteins to be
sequestered away from the normal cellular machinery [8,9,10].
There are two main routes for eukaryotic intracellular protein
clearance: ubiquitin proteasome system (UPS) and autophagy
(referred as macroautophagy)-lysosome pathways. The UPS and
autophagy degradation systems are functionally coupled and
linked by a multi-domain protein adapter, p62,which is able to
bind ubiquitinated proteins and lead them to autophagosomes for
degradation [11]. It was also found that p62 controls aggresome
formation and autophagic degradation [12]. Suppression of the
proteasome by bortezomib promotes autophagy in colon cancer
cells [13], while inhibition of autophagy increases levels of
proteasome substrates, such as p53 protein [14].The search for
autophagy client proteins is important to understand how
autophagy protects tumor cells from being killed.
NF-kB activation typically relies on two major pathways:
canonical and non-canonical. The canonical pathway involves
degradation of the NF-kB inhibitor I-kBa, and the non-canonical
pathway indicates degradation of NF-kB precursor protein p100.
Both I-kBa and p100 proteins were reported to be degraded via
UPS [15]. However, a recent study demonstrated that bortezomib
induces canonical NF-kB activation rather than inhibition of NF-
kB activation by down-regulation of constitutive I-kBa expression
in multiple myeloma cells [16]. Others found that treatment of
primary effusion lymphoma cells with bortezomib failed to inhibit
NF-kB activation [17].
Gene expression profiling in diffuse large B-cell lymphoma
(DLBCL) has revealed that this disease has at least three subtypes:
germinal centre B-cell like (GCB)-, activated B-cell like (ABC)-and
primary mediastinal B-cell lymphoma (PMBL) [18,19]. Among
them, the ABC-DLBCL has higher levels of constitutive NF-kB
activity [19]. A previous study showed that DLBCL cells are
resistant to treatment with bortezomib alone [20,21], whereas the
combination of bortezomib with other chemotherapeutic drug
significantly increased response in ABC-DLBCL compared with
GCB-DLBCL [20]. The anti-malaria drug chloroquine (CQ) has
been used as an autophagy inhibitor and many studies have shown
that CQ strongly potentiates anti-cancer effects of a variety of
chemotherapeutic drugs. Treatment with CQ alone induces
lymphoma cell death by-passing the mitochondria/caspase-
dependent pathway [22]. It is unknown why DLBCL cells are
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whether autophagy plays a role in this resistance.
Our previous study showed that bortezomib kills chronic
lymphocytic leukemia cells largely dependent on blocking Bax
degradation [6]. In this study, we aimed to determine the
resistance factors of DLBCL cells to bortezomib and whether
bortezomib induces autophagy during treatment. We demonstrate
that bortezomib induces I-kBa degradation which is removed by
the autophagic process and activates NF-kB transcriptional
activity. Blocking autophagy by CQ potentiates bortezomib-
induced accumulation of I-kBa and DLBCL cell death. Taken
together, these data suggest a therapeutic role for blockade of this
pathway.
Materials and Methods
Cells, cell culture and treatment
Primary lymphoma cells were obtained from single cell
suspensions of lymph node biopsies after obtaining written
informed consent and approval by the East London and the City
HA Local Research Ethics Committee 3with REC reference
number: 05/Q0605/140 in accordance with the Declaration of
Helsinki. DLBCL cell lines used in this study included: the GCB
type DoHH2, Su-DHL4, and Su-DHL10and the ABC type Su-
DHL8 [23,24]. Cells were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum, 25 mM
HEPES, and 2.0 mM L-glutamine at 37uC in a 5% CO2
humidified incubator.
Flow cytometry assay cell death and mitochondrial
function
Cell death was determined by PI dye exclusion. After treatment,
cells were incubated with 10 mg/ml propidium iodide (PI) (Sigma,
Poole UK) and the integrity of cell membrane was measured by
flow cytometry using a FACS Calibur (Becton Dickinson) on the
FL3-H channel. To determine the mitochondrial membrane
potential (DYm), after treatment cells was stained with 40 nM
Tetramethylrhodamine methyl ester(TMRM) (Invitrogen, Paisley,
UK) at 37uC for 15 min and changes in DYm were measured on
the FH2-H channel [25]. To measure the production of reactive
oxidative species (ROS), cells were stained with 40 mM dihy-
droethidium (Polyscience-Park Scientific Ltd, Northampton, UK)
at 37uC for 15 min and increases in ROS production were
measured on the FH3-H channel [25].
Drug uptake
Cells (2610
5/ml) were subjected to flow cytometry for
10 seconds in pre-warmed culture medium to establish a base-
line of cellular auto-fluorescence. The assay was interrupted, and
daunorubicin (100 mg/ml) was added. Red fluorescence was
measured continuously at a flow rate of 200 cells per second for
100 seconds on a log scale [26].
Proteasome and caspase activity assays
Cytosolic proteins (50 mg) were diluted to 90 mlw i t h
fluorogenic assay buffer (20 mM HEPES-KOH, pH 7.4,
10 mM DTT, 10% sucrose, 1.0 mM EDTA, 0.1% CHAPS).
The reaction was initiated by addition of 10 mlo f4 0 0mM( f i n a l
concentration was 40 mM) fluorescent substrates, Suc-LLVY-
AMC (Enzo Life Science, Exeter, UK) for the chymotrypsin-like
peptidase activity of the 20 S proteasome or Ac-DEVE-AFC
(Merck-Calbiochem, Nottingham, UK) for the caspase-3 activity.
The cleavage reaction was carried out at 37uC for 15 min. The
fluorescence at 400/505 nm for caspase-3 or at 380/460 nm for
proteasome was measured with a BMG LABTECH POLARstar
OPTIMA Microplate Reader (Offenburg, Germany). Measure-
ments were calibrated against a standard linear regression curve
of AFC or AMC. Caspase or proteasome activity was defined as
mM AFC or AMC release per mg protein per hour (mM/hr/mg
protein) [6].
Preparation of cytosol and nuclear protein extracts
Cytosolic or nuclear proteins were extracted using the Nuclear
Complex Co-IP Kit (Active Motif Europe, Rixensart, Belgium)
according to the manufacturer’s instruction. Briefly, cells were
swelled by incubation with hypotonic buffer containing protease
inhibitor or phosphatase inhibitor cocktails at 4uC for 15 min and
then mixed with detergent solution (1:20 dilution). Cytosol and
nucleus were separated by centrifugation at 14,0006g and nuclear
fraction was washed once with the hypotonic buffer. The nuclear
proteins were extracted with the Complete Digestion Buffer. The
purities of cytosolic and nuclear proteins were examined by
Western blotting using LDH for cytosol and Rb antibody for
nuclear fractions.
Co-immuno-precipitation (Co-IP)
Co-IP was performed using the Nuclear Complex Co-IP Kit
and Dynabeads protein A (Invitrogen). Dynabeads in 50 mlo fI P
buffer was incubated with 2 mg anti-IkB-a antibody or rabbit IgG
for 10 min at room temperature on a rotator. After three washes
with IP buffer, Dynabeads protein A coated with antibody or IgG
was mixed with 300 mg proteins and incubated for 20 min at room
temperature on a rotator. Protein complex was then eluted with
NuPAGE LDS sample buffer mixed with reducing agent
(Invitrogen).
Measurement of NF-kB p65 DNA binding activity
Nuclear proteins (10 mg) were used to determine DNA binding
activity of NF-kB p65 using TransAM NF-kB p65 kit (Active
Motif). NF-kB p65 bound to the immobilized oligonucleotide
containing a p65 binding site was detected by ELISA with
colorimetric reagent.
Determine NF-kB DNA binding activity by
Electrophoretic Mobility Shift Assay
NF-kB DNA binding activity was carried out by electrophoretic
mobility shift assay (EMSA). This assay is based on the fact that
DNA-protein complexes migrate slower than non-bound DNA in
native polyacrylamide, resulting in a ‘‘shift’’ in migration of the
labeled DNA band. Nuclear protein-DNA complexes were
extracted by NE-PERH Nuclear and Cytoplasmic Extraction
Reagents (Pierce-Thermo Scientific). Double stranded NF-kB
consensus oligonucleotides 59-AGT TGA GGG GAC TTT CCC
AGG C-3 and 39-TCA ACT CCC CTG AAA GGG TCC G-59
(Santa Cruz) containing a putative binding site for NF-kB were
end-labeled with biotin using Biotin 39 End DNA Labeling Kit
(Pierce-Thermo Scientific). Bands were detected by ‘‘The Light
Shift
TM Chemiluminescent EMSA kit’’ (Pierce-Thermo Scientific)
using a non-isotopic method to detect DNA-protein interactions.
Biotin end-labeled DNA duplex of NF-kB was incubated with the
nuclear extracts (10 mg nuclear proteins). After the reaction the
DNA-protein complexes were subjected to a 6% DNA retardation
gel (Invitrogen) and transferred to a positively charged nylon
membrane (Pierce-Thermo Scientific). After transfer the mem-
brane was immediately cross-linked for 15 min on a Gene Flash
UV transilluminator (Syngene). A chemiluminescent detection
method utilizing a luminol/enhancer solution and a stable
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by the manufacturer, and membranes were exposed under
Luminescent Image Analyzer (FujiFilm) for visualization.
Western blotting
Proteins were extracted with CelLytic
TM M cell Lysis Reagent
(Sigma) supplied with protease inhibitor and phosphatase inhibitor
cocktails (Sigma). Protein concentration was determined by
Bradford method, using Bio-Rad Bradford reagent. Proteins were
mixed with NuPAGE LDS Sample Buffer (Invitrogen) and boiled
for 5 min before analysis by Western blotting. Proteins were
subjected to 4–20% NuPAGE gels (Invitrogen) and transferred
onto PVDF membrane (Sigma) at 20 V for 1 hour by semi-dry
transfer. PVDF membrane was blocked with 5% non-fat milk in
PBST or TBST for 1 hour and then incubated with primary
antibodies overnight at 4uC against the following: Bcl-2 (100), NF-
kB p65 (F-6), ubiquitin (P4D1), Bcl-xS/L (S-18), I-kBa (FL), LDH
(H-160), and PARP (H-250) (Santa Cruz); b-actin (AC-74), FLIP
and p62/SQSTM1 (Sigma); IL-6 (R&D Systems); CHOP,
phospho-IkBa-(Ser32/36), Rb, LC3B, phospho-NF-kB p65-
(Ser536), and Mcl-1, NF-kB p65 (RelA), RelB, c-Rel,and NF-kB
p50 antibodies (Cell Signaling Technology-New England Biolabs,
Hitchin, UK). Bound antibodies were detected using appropriate
HRP-conjugated secondary antibodies (Santa Cruz), visualized by
GeneSnap (SynGene, Cambridge, UK) after adding ECL plus
(GE Healthcare Life Science), and the density of each band was
analyzed with the Gelscan V5.1 software.
Immuno-staining and fluorescent microscopy
Cells were fixed and permeabilized on slides with Cytofix/
Cytoperm reagents (BD) and blocked with a buffer consisting of
0.1% saponin and 5% serum (the type of serum corresponding to
the isotype of the secondary antibody). Cells were co-stained with
p62 antibody (mouse 1:20 or rabbit 1:150), monoclonal anti-
ubiquitin antibody (1:20), polyclonal anti-LC3 antibody (1:100), or
polyclonal anti-I-kBa (1:20) for 1 hour at room temperature. After
washing with PBST, cells were incubated with Alexa-Fluor
conjugated secondary antibodies at a 1:100 dilution for Alexa-
Fluor 488 and 1:50 dilution for Alexa-Fluor 546 (Invitrogen).
Slides were washed for 3 times with PBST, stained with 50 ng/ml
DAPI (49,6-diamidino-2-phenylindole), air-dried at 4uC in the
dark, and mounted in ProLongH Gold anti-fade reagent (Invitro-
gen) before being viewed under an Olympus BX40 fluorescence
microscope (Artisan Scientific Corporation, USA).
Transfection of plasmid
Plasmid DNA was extracted using Plasmid DNA extraction kit
(Sigma). Transfection was performed using Nucleofector
TM II
device and Nucleofector Reagent C (Lonza Biologics, Slough,
UK). Su-DHL8 cells (5610
6/ml) in the Reagent C were mixed
1 mg pBABE-puro mCherry-EGFP-LC3B construct (Addgene)
and the program D-023 was used for the transfection.
Statistical analysis
Data are presented as means 6 standard deviation (SD) and
were analyzed by build-in t test, Correlation and ANOVA with
replications using Microsoft Excel and Prism software. Change
where P#0.05 was considered significant. The synergistic effect of
chloroquine (CQ) on bortezomib-induced cell death was analyzed
by the CalcuSyn software. In this analysis, the general range of CI
values of less than 0.90 indicate various levels of synergy, while
values of 0.90–1.10 indicate addition, and .1.10 indicates
antagonism [27].
Results
Bortezomib-induced proteasome inhibition mediates
autophagy
In keeping with previous studies [20,21], we found that cells
obtained from lymph node biopsies of previously untreated
DLBCL patients were resistant to bortezomib-mediated killing.
To understand the mechanism for this, we assessed the sensitivity
of lymphoma cell lines to bortezomib-induced proteasome
inhibition and cell death. These cell lines showed equal capacity
of drug uptake (Figure S1). Bortezomib at the concentration of
10 nM reached almost maximum inhibition on the proteasome
activity in these cell lines (Figure 1A). In agreement with a previous
study [28], the sensitivity of these DLBCL cell lines to bortezomib-
induced cell death was not associated with proteasome inhibition
(Figure 1B). The ABC-DLBCL cell line Su-DHL8 showed a
similar sensitivity to bortezomib-induced cell death compared with
the GCB-DLBCL cell line DoHH2 (Figure 1B).
Accumulation of poly-ubiquitinated proteins as a result of
bortezomib-induced proteasome inhibition was detected by
Western blotting (Figure 1C). The UPS and autophagy systems
are functionally linked and inhibition of UPS stimulates autoph-
agic activity, possibly as a compensatory mechanism [29,30]. We
therefore tested whether bortezomib-induced accumulation of
ubiquitinated proteins triggers autophagy in DLBCL cells.
Bortezomib induced a dose-dependent LC3-II accumulation, a
hallmark of autophagy activation, in both sensitive and resistant
cell lines but LC3-I was neither detected in control cells nor in
bortezomib-treated DLBCL cells (Figure 1C). The amounts of
LC3-II accumulation were strongly correlated to those of
accumulated poly-ubiquitin (Correlation P,0.0001, Figure S2).
To further confirm the role of bortezomib on the induction of
autophagy, we determined the LC3-II aggregation by immuno-
staining on cells treated with bortezomib. Larger LC3-II
aggregates were formed after treatment with bortezomib in both
the bortezomib-sensitive DoHH2 and resistant Su-DHL10 cell
lines, demonstrating the formation of autophagosomes (Figure 1D).
Autophagosome formation was also confirmed in mCherry-EGFP-
LC3B transfected Su-DHL8 cells. Because EGFP is acid-labile and
mCherry is acid-stable, transfection of the mCherry-EGFP-LC3B
construct allows visualization of both autophagosomes (neutral)
and autolysosomes (acidic) [31]. After treatment with bortezomib
for 6 or 18 hours, most of the cells contained red colored
structures, indicating autolysosomes (Figure 1E). These results
demonstrate that treatment of DLBCL cells with bortezomib
induces autophagy which enables cells to remove accumulated
proteins.
Bortezomib induces cellular stress responses
Inhibition of proteasome activity causes accumulation of
ubiquitinated and/or mis-folded proteins. This could lead to
cellular stress including mitochondrial and ER stress, which in
turn triggers either cell death and/or the autophagic process
[6,29]. We therefore determined whether treatment with
bortezomib induces these cellular stress responses in DLBCL
cell lines and whether these responses are pro- or anti-apoptotic
reactions. Cellular stress after treatment with bortezomib was
firstly observed at the mitochondrial levels, as increased
generation of ROS (Figure 2A) and decreased DYm (Figure 2B).
DLBCL cells showed similar sensitivity patterns to bortezomib-
mediated mitochondrial depolarization (Figure 2B) and cell death
(Figure 1B), suggesting that bortezomib-induced cytotoxicity is
via the mitochondria-dependent pathway. Perturbations of ER
homeostasis by proteasome inhibition affects protein folding and
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It was reported that accumulation of CHOP could mediate ER
stress-associated apoptosis [32].Bortezomib induced a dose-
dependent accumulation of CHOP protein (Figure 2C), the
levels of which were not associated with the sensitivity of
bortezomib-induced cell death (Figure 2C and Figure 1B). These
data suggest that bortezomib-induced cell death was not caused
by ER stress.
Figure 1. Bortezomib-induced proteasome inhibition and autophagy. (A) Bortezomib-induced proteasome inhibition. Proteasome activity
was measured by fluorogenic assay after cells were treated with bortezomib (Millennium) for 16 hours. Error bars are omitted for clarity. (B)
Bortezomib-induced cell death. Cell death was determined by flow cytometry of PI positive cells (PI
+) after 24 hours treatment. Data presented (A and
B) are mean 6 SD from three independent experiments. Significant difference in cell death was observed by ANOVA with replicated data between
DoHH2 and SU-DHL4 and Su-DHL10 (*P,0.0001) whereas no difference was observed between DoHH2 and Su-DHL8 (**P.0.05). (C) Bortezomib-
induced accumulation of poly-ubiquitinated proteins and autophagy protein LC3-II. Cells were treated with bortezomib for 24 hours (DoHH2 and Su-
DHL8) or 48 hours (Su-DHL4 and Su-DHL10). Cell pellets were lysed with 1% SDS containing lysis buffer. After heated at 99uC for 10 min, proteins
were cleared by ultracentrifugation. Monoclonal anti-ubiquitin antibody was used at 1:200 dilution. Polyclonal anti-LC3B antibody was used at 1:1000
dilution and b-actin was used as a loading control. Numbers under each group of Western blots are ratios of ubiquitin/b-actin or LC3-II/b-actin which
were measured by densitometry. (D) Autophagosome formation. After treatment with 20 nM bortezomib for 24 hours, fixed and permeabilized cells
on slides were stained with the anti-LC3B antibody (1:100 dilution) and then anti-rabbit Alexa Fluor-488 (1:100 dilution). DAPI was used to indicate
nuclear localization. Arrow heads indicate autophagosomes. (E) Formation of autophagosomes and autolysosomes. Cells were transfected with 1 mg
pBABE-puro mCherry-EGFP-LC3B plasmids for 48 hours and then treated with 20 nM bortezomib for 24 hours.
doi:10.1371/journal.pone.0032584.g001
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autophagosomes
When the proteasome is inhibited, ubiquitinated proteins can
also be digested by autophagy [14]. The adaptor protein p62
recruits ubiquitin and its conjugated proteins, leading them to the
autophagosome by also interacting with the autophagy protein LC3
[33,34]. Immunostaining experiments showed that ubiquitin (red)
and p62 (green) were separately localized in untreated Su-DHL4
cells. After treatment with 10 nM bortezomib for 24 hours,
ubiquitin was recruited by p62, shown by co-localization of red
(ubiquitin) and green (p62) merged into large, dense, yellow
aggregates.Accumulationofubiquitinandp62aggregatesincreased
in both number and size when cells were treated with both CQ and
bortezomib (Figure 3A). Similar results were observed in the other
cell lines (Figure S3 and results not shown). To determine whether
p62 directed protein aggregates to autophagosomes, cells were co-
stained with p62 (red) and autophagosome protein LC3 (green). In
the control cells, the patterns of both LC3 and p62 distribution in
the cytosol were either as smeared or in small dots. Treatment with
either bortezomib or CQ alone increased formation of autophago-
somes, shown as increased LC3 granules. Combination of both CQ
and bortezomib showed stronger accumulation of LC3 and p62
aggregates (Figure 3B and Figure S4).
I-kBa is a short-lived protein, previously thought to rely on UPS
for degradation [35]. However, it was recently found that I-kBa
protein degraded in multiple myeloma cells and some cancer cell
lines during treatment with bortezomib [16,36]. We show that
uiquitination of I-kBa was detected in Su-DHL8 cells in the resting
stage and increased after treatment with bortezomib or/and CQ for
3 to 6 hours. Bortezomib-induced accumulation of poly-ubiquiti-
nated proteins increased when combined with the autophagy
inhibitor CQ (Figure 3C). We therefore tested whether bortezomib-
inducedI-kBa degradationalso occursinDLBCL cellsandwhether
this degradation is associated with enhanced autophagy. To test
whether I-kBa degradation by autophagy is associated with p62
aggregation, DLBCL cells were co-stained with p62 (red) and I-kBa
(green) after treatment with CQ and 20 nM bortezomib up to
24 hours. I-kBa and p62 co-localization was observed in both
controlandbortezomib-treatedcellsfor3,6 and 24 hours,shown as
larger yellow speckles, although the intensity of I-kBa green
fluorescencewasreducedinbortezomib-treated cells.Accumulation
of I-kBa/p62 aggregates was intensified when cells were treated
with both CQ and bortezomib (Figure 3D and Figure S5),
indicating blocking autophagy prevented I-kBa and p62 degrada-
tion. These results demonstrate that p62 recruits ubiquitinated
proteins, such as I-kBa, and leads them to autophagosomes for
Figure 2. Bortezomib-induced cellular stress responses. Bortezomib-induced ROS generation (A) and mitochondrial depolarization (B). Cells
were treated with 20 nM (A) or different concentrations of bortezomib for 18 hours (DoHH2 and Su-DHL8) or 24 hours (Su-DHL4 and Su-DHL10). ROS
or DYm was determined by flow cytometry after cells were stained with HE or a DYm-dependent dye TMRM, respectively. (A) A typical result from
three independent experiments performed. (B) Data presented are mean 6 SD from three independent experiments. By comparison with the DoHH2
cell line, significant differences by ANOVA were observed for Su-DHL4 and Su-DHL10 (*P,0.001), whereas no significant difference was observed for




PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32584Figure 3. Role of p62 on sequestration of ubiquitin and I-kBa. Su-DHL8 cells were pre-incubated with or without 50 mM CQ for 1 hour and
then treated with indicated concentration of bortezomib for 24 hours. (A) Co-localization of ubiquitin and p62. Cells on slides were co-stained with
monoclonal anti-ubiquitin (1:20 dilution) and polyclonal anti-p62 (1:100 dilution) antibodies, and probed with Alexa Fluor anti-mouse IgG 546 (1:50
dilution) and anti-rabbit IgG-488 (1:100 dilution) antibodies. (B) Co-localization of p62 and LC3-II. Cells on slides were co-stained with monoclonal
anti-p62 (1:20 dilution) and polyclonal anti-LC3B (1:100 dilution), and probed with Alexa Fluor anti-mouse IgG 546 (1:50 dilution) and anti-rabbit IgG-
488 (1:100 dilution) antibodies. (C) Bortezomib-induced ubiquitination of I-kBa and accumulation of LC3-II protein. After treatment with 20 nM
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tion between I-kBa and p62 was detected in both the resting stage
and after treatment with bortezomib (Figure 3E). These results
demonstrate that p62 could be a carrier to bring ubiquitinated I-
kBa to autophagosomes for degradation.
Inhibition of autophagy by CQ prevents bortezomib-
induced I-kBa degradation but not phosphorylation
NF-kB activation is initiated by phosphorylation and conse-
quently degradation of its inhibitor protein I-kBa. Bortezomib
induced dose-dependent I-kBa degradation was coupled with
increased phosphorylation, as detected by Western blotting in four
DLBCL cell lines. For the 4 cell lines tested bortezomib-induced I-
kBa degradation was significantly (p,0.01) inhibited by pre-
treatment with the autophagy inhibitor CQ (Figure 4A and 4B).
Inhibition of autophagy did not block bortezomib-mediated
phosphorylation of I-kBa. In contrast, the levels of phosphorylated
I-kBa were significantly (p,0.01) increased (Figure 4A and 4C).
This indicates that the role of CQ is to prevent I-kBa degradation
by autophagy but not upstream of its phosphorylation. Bortezo-
mib-induced I-kBa degradation was also observed in primary FL
and DLBCL cells (Figure 4D).
Inhibition of autophagy blocks bortezomib-induced NF-
kB activation
We next determined whether bortezomib induces NF-kB
activation. The ABC-DLBCL cell line Su-DHL8 showed consti-
tutive NF-kB activity, as detected by nuclear localization of NF-kB
family proteins, mainly RelB and p50. Treatment with bortezomib
significantly increased NF-kB family proteins RelA/p65 and p50
nuclear translocation. Modestly increased RelB and c-Rel nuclear
translocation were also observed after treatment with bortezomib.
However, p52 nuclear translocation was not detected. Blocking
autophagy by CQ significantly decreased RelA/p65, RelB, c-Rel
and p50 nuclear protein levels (Figure 5A and 5B). Immuno-
precipitation results showed that bortezomib reduced the interac-
tion between NF-kB RelA/p65 and I-kBa and co-treatment with
CQ prevented bortezomib-induced disruption of NF-kB and I-
kBa binding (Figure 5C and 5D). Consistent with the co-immuno-
precipitation results, bortezomib remarkably increased NF-kB
RelA/p65 DNA binding activity. Importantly, treatment with CQ
blocked bortezomib-induced DNA binding activity (Figure 5E).
Bortezomib-mediated NF-kB activation was also confirmed by
electrophoretic mobility shift assay. After treatment for 6 hours,
NF-kB activity was remarkably enhanced bortezomib. Bortezo-
mib-induced NF-kB activation was also reduced by co-treatment
with CQ (Figure 3F). Taken together, these results demonstrate
that bortezomib induces canonical NF-kB activation by triggering
the autophagic degradation of I-kBa.
Bortezomib enhances de novo protein synthesis of NF-kB
target genes
We next determined whether bortezomib-mediated activation of
NF-kB triggers protein synthesis of its target genes. NF-kBi t s e l fa n d
its inhibitor I-kBa are among NF-kB target genes [37]. We detected
that treatment with bortezomib induced increased protein expres-
sion of the serine-536 phosphorylated, but not non-phosphorylated,
form of NF-kB p65. Pre-treatment of lymphoma cells with the
protein synthesis inhibitor cycloheximide (CHX) completely blocked
bortezomib-induced up regulation of phosphorylated NF-kBa n d
the levels of NF-kB were also reduced (Figure 6A). Bortezomib-
mediated up-regulation of phosphorylated I-kBa was completely
diminished by pre-treatment with CHX. The levels of the un-
phosphorylated form of I-kBa were also remarkably reduced by
CHX (Figure 6A). This suggests that de novo synthesized NF-kBa n d
I-kBa may be more susceptible to IKK-mediated phosphorylation.
The anti-apoptotic BCL-2 family proteins are also targets of NF-kB.
As a result of NF-kB activation, MCL-1, BCL-XL and BCL-2 were
up-regulated by bortezomib and increased expression of these
proteins was partially inhibited when protein synthesis was blocked
(Figure 6B). Protein levels of MCL-1, BCL-XL and BCL-2 were not
increased while cells were cultured up to 18 hours without treatment
(Figure S6). Other NF-kB target proteins, such as IL-6 and FLIP,
were also up-regulated by treatment with bortezomib (Figure 6C).
These results indicate that treatment with bortezomib induced de-
novo protein synthesis and this is associated with NF-kB activation.
Blocking autophagy potentiates proteasome inhibitor-
mediated cell death
To test whether autophagy acts as a resistant factor with this
treatment, bortezomib-induced cell death was determined in the
presence or absence of CQ. Treatment with CQ up to 50 mMd i d
not induce significant cell death (Figure S7). Bortezomib-induced
cell death was significantly increased (P,0.01) when combined with
CQ. The maximum cell death-induced by CQ and bortezomib was
reached in 24 hours for the bortezomib-sensitive cell lines, DoHH2
and Su-DHL8 and in 48 hours for the resistant cell lines, Su-DHL4
and Su-DHL10 (Figure 7A). The synergistic effect of CQ on
bortezomib-induced cell death was analyzed using the CalcuSyn
software [27]. CI values were all lower than 0.9, indicating synergy
(Figure 7B). This showed that combination with CQ has a great
potential to increase the sensitivity of DLBCL cell lines to
bortezomib-induced cell death. The sensitization effect of CQ on
bortezomib-induced apoptosis was determined by increased cas-
pase-3activity(FigureS8)andincreasedPARPcleavage(Figure7C).
We next tested whether inhibition of autophagy could overcome
resistance of primary lymphoma cells to bortezomib-induced cell
death. When FL and DLBCL primary tumor cells were treated with
20 nM bortezomib with or without 30 mM CQ, both FL and
DLBCL primary cells were resistant to bortezomib (P=0.062) but
sensitive to CQ-induced cell death (P=0.0003). The combination of
CQ and bortezomib significantly sensitized lymphoma cells to
treatment compared with using bortezomib (P=0.0005) or CQ
alone (P=0.002) (Figure 7D). These data confirmed that inhibition
of autophagy by CQ significantly synergized with bortezomib-
induced lymphoma cell death by apoptosis.
Discussion
This study demonstrated that treatment of DLBCL cells with
bortezomib induces autophagy which eliminates ubiquitinated I-kBa.
bortezomib with or without CQ, proteins were extracted from Su-DHL8 cells with 1% SDS and loaded onto 4–20% NuPAGE. Polyclonal anti-IkBa
(1:200) and monoclonal anti-ubiquitin (1:200) were used to probe specific proteins. (D) Co-localization of p62 and I-kBa. Cells on slides were co-
stained with polyclonal anti-I-kBa antibody (1:20) and monoclonal anti-p62 antibody (1:20) and then probed with Alexa Fluor anti-mouse IgG 546
(1:50 dilution) and anti-rabbit IgG-488 (1:100 dilution). Arrows indicate p62-I-kBa aggregates. (E) Detection of p62 and I-kBa interaction by Co-IP.
Polyclonal anti-I-kBa antibody (2 mg) or normal rabbit IgG was coated onto Dynabeads protein A and 300 mg proteins were used for IP. Monoclonal
anti-p62 antibody (1:100 dilution) and polyclonal anti-I-kBa antibody were used to detect p62/I-kBa protein complex.
doi:10.1371/journal.pone.0032584.g003
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32584I-kBa is an inhibitor of NF-kB and sufficient levels of I-kBa protein
are essential to keep NF-kB in the cytosol, preventing its
transcriptional activity in the nucleus. Decreased levels of I-kBa
could lead to NF-kB activation and cause further resistance of cancer
cells to treatment [16,38]. We demonstrate that blocking autophagy
by CQ increased complex formation of I-kBa with NF-kBi nt h e
cytosol and prevented bortezomib-induced NF-kBa c t i v a t i o n .
Bortezomib is the first proteasome inhibitor and has been
approved to treat relapsed multiple myeloma and mantle cell
lymphoma [9,39,40]. A main anti-cancer effect of bortezomib is
inhibition of NF-kB activation induced by TNF-a or TRAIL via
blockade of I-ka degradation [2,3]. Recent studies showed that
constitutive NF-kB activity and microenvironment induced NF-kB
activation in cancer cells can cause bortezomib-resistance [41,42].
Figure 4. Bortezomib-induced I-kBa phosphorylation and degradation. DoHH2, Su-DHL4, Su-DHL8 and Su-DHL10 cell lines were pre-treated
with 50 mM CQ for 1 hour and then treated with 10 nM or 20 nM bortezomib for 24 hours. Proteins were extracted in the presence of phosphatase
inhibitor cocktails. Polyclonal anti-phospho-I-kBa (Ser32/36) (1:1000) and anti-I-kBa (1:200) antibodies were used for Western blotting. Ratios of I-kBa/
b-actin (B) and P-I-kBa/b-actin (C) were analyzed by densitometry. Data represent mean 6 SD from the four cell lines tested (*P,0.001). (D)
Bortezomib-induced I-kBa degradation in primary lymphoma samples. Single suspension cells were treated with 20 nM bortezomib for 24 hours and
proteins were extracted for Western blotting. Polyclonal anti-I-kBa antibody was used at 1:200 dilution.
doi:10.1371/journal.pone.0032584.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32584Figure 5. Bortezomib-induced NF-kB activation. Su-DHL8 cells were treated with 20 nM bortezomib with or without 50 mg/ml of CQ. (A and B)
Effects of bortezomib or/and CQ on the levels of NF-kB proteins. Cytosolic and nuclear proteins were extracted from Su-DHL8 cells. 15 mg cytosolic or
nuclear proteins were subjected to 4–20% NuPAGE gel. Anti-NF-kB RelA/p65, RelB, cRel, p50 and p52 rabbit antibodies were used at 1:3000 dilution.
Monoclonal Rb (the nuclear protein marker), and polyclonal LDH (the cytosolic protein marker) antibodies were used at 1:2000 and 1:500 dilution,
respectively. Western blots presented are representative of 3 independent experiments performed. (B) Data analysis of NF-kB nuclear translocation.
Significantly increased p65 or p50 protein levels after treatment with bortezomib (*P,0.05) was compared with their controls and analysed by t test
(n=3). Chloroquine-mediated inhibition on the nuclear translocation of RelA/p65, RelB, cRel and p50 was compared with their controls and treated
with bortezomib alone. Significantly decreased nuclear protein levels were analyzed by t-test. (C) Effects of bortezomib or/and CQ on interaction
between NF-kB and I-kBa. Dynabeads proteins A was coated with 2 mg of polyclonal anti-I-kBa antibody or normal rabbit IgG and then incubated
with 300 mg protein. Interaction of I-kBa with NF-kB was determined by Western blotting with monoclonal anti-NF-kB antibody. IgG-Hv indicates IgG
heavy chain (55 kD). Numbers under each pairs of bands are ratios of NF-kB/heavy chain. (D) Statistical data from three independent IP experiments
analyzed by t test. (E) Effects of bortezomib or/and CQ on NF-kB RelA/65 DNA binding activity. Nuclear proteins were extracted using Nuclear Co-IP
Kit. 10 mg nuclear proteins were used for the DNA binding assay. NF-kB DNA binding activity was determined using TransAM
TM NF-kB p65 ELISA Kit.
Data represent mean 6 SD from 3 independent experiments. (F) Effects of bortezomib or/and CQ on NF-kB/cRel DNA binding activity. Su-DHL8 cells
were treated with 20 nM bortezomib with or without 50 mM CQ for 6 hours. Protein-DNA complexes were extracted and bound with biotin-labeled
NF-kB/cRel DNA binding site. Data represent two separate results from four independent experiments.
doi:10.1371/journal.pone.0032584.g005
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32584Figure 6. Bortezomib-induced protein synthesis. Su-DHL-8 cells were pre-treated with 50 mg/ml CHX for 1 hour and then incubated with
20 nM bortezomib for indicated period of time. (A) Effect of CHX on NF-kB and I-kBa. Monoclonal anti-NF-kB (1:200) and anti-phospho-I-kBa (1:1000),
and polyclonal anti-phospho-NF-kB (1:1000) and I-kBa were used for the Western blotting. (B) Effect of CHX on anti-apoptotic proteins. Polyclonal
anti-Mcl-1 (1:1000) and Bcl-XL (1:200) antibodies, and monoclonal anti-Bcl-2 antibody (1:200) were used for Western blotting. (C) Effect of CHX on
other NF-kB target proteins. Goat anti-IL-6 (1:1000) and rabbit anti-FLIP (1:2000) antibodies were used for Western blotting. Numbers on the bottom
of each lane are ratios of indicated protein to b-actin.
doi:10.1371/journal.pone.0032584.g006
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e32584Figure 7. Synergistic effect of CQ on bortezomib-induced cell death. Cells were pre-treated with 50 mM CQ for I hour and then treated with
bortezomib for 24 to 48 hours. (A) Determining cell death by flow cytometry. After treatment, cells were stained with 10 mg/ml PI and PI positive cells
were counted as died cells. Data represent mean 6 SD from 3 independent experiments. Asterisk (*) indicates P,0.01, significantly increased
sensitivity analyzed by ANOVA. (B) Synergistic effect of CQ on bortezomib. Synergy was analyzed by CalcuSyn and synergy level was setup lower than
0.9. (C) PARP cleavage. PARP cleavage was analyzed by Western blotting using polyclonal anti-PARP antibody (1:500). Lower bands (89 kD) indicate
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e32584Of note, it has been recently shown that bortezomib does not
prevent I-kBa degradation; in fact, it causes I-kBa degradation in
multiple myeloma cells. This suggests that bortezomib-induced I-
kBa degradation is not occurring through the UPS pathway [16].
Previous studies showed that ABC-DLBCL cell lines (OCI-Ly3
and OCI-Ly10) had high nuclear NF-kB DNA binding activity,
constitutive I-kB kinase (IKK) activity and rapid I-kBa degrada-
tion that was not seen in GCB-DLBCL cell lines, such as Su-DHL-
4. Abrogation of NF-kB activity by transduction of domain
negative form of IKKb was toxic to ABC-DLBCL cell but not to
GCB-DLBCL cells, suggesting ABC type DLBCL cells rely on
NF-kB for survival (19). Although ABC-DLBCL has constitutively
activated NF-kB [19,20], both GCB and ABC-DLBCL cells are
resistant to bortezomib. We found that the sensitivity of DLBCL
cells to bortezomib-induced apoptosis is independent of their
types, as the Su-DHL-8 cell line (ABC-DLBCL) has constitutively
activated NF-kB but is relatively sensitive to bortezomib compared
with Su-DHL-4 and Su-DHL-10 (GCB-DLBCL). The differential
sensitivities of these cells to bortezomib are more or less dependent
on their constitutive ratios of BCL-2/Bax (results not shown). Our
previous study showed that Bax is a short-lived protein and
treatment with bortezomib leads to Bax accumulation in primary
CLL cells and DLBCL cell lines [6]. We therefore reasoned that I-
kBa, also a short-lived protein, could be accumulated in response
to bortezomib. However, our results demonstrated that treatment
with bortezomib induced I-kBa degradation in DLBCL cell lines
as well as in primary FL and DLBCL cells, in agreement with the
finding by Hideshima and colleagues in multiple myeloma cells
[16].
Treatment with bortezomib induced autophagy in DLBCL
cells. This is shown by accumulation of the autophagy marker
LC3-II in parallel with I-kBa degradation. Autophagy and UPS
are the major routes for intracellular protein degradation and the
two pathways have previously been thought to be largely distinct
[14]. UPS degrades short-lived proteins such as I-kBa, Bax and
p53 while autophagy is a process to degrade long-lived proteins
and organelles [43]. However, the short lived protein p53
accumulates when autophagy is inhibited [14], suggesting that
the two degradation systems collaborate and compromise each
other to remove unwanted proteins. We now show that treatment
with bortezomib leads to accumulation of ubiquitinated proteins
and CHOP, indicating that proteasome inhibition causes ER stress
and that ubiquitin/ubiquitinated proteins translocate to p62 rich
loci to form larger aggregates. Co-staining with p62 and LC3-II
showed that these aggregates also contain LC3-II. p62 has multi-
functional domains which can bind to ubiquitinated proteins and
LC3 simultaneously, leading to ubiquitinated proteins being
degraded by autophagy [31]. I-kBa co-localization and interaction
with p62 was found before and after treatment with bortezomib. I-
kBa staining and binding became weaker after treatment,
consistent with the observed reduced levels of I-kBa shown by
Western blotting. This suggests that I-kBa may be degraded by a
route which is independent of the proteasome. It has been shown
recently that proteasome inhibition induces accumulation of both
ubiquitinated and non-ubiquitinated misfolded proteins in the
aggresome, so that degradation by autophagy is not dependent on
substrate ubiquitination [44]. However, I-kBa ubiquitination was
clearly induced by bortezomib and was associated with I-kBa
phosphorylation. It is unknown whether bortezomib-induced
formation of p62/ubiquitin aggregates constitutes an aggresome
and whether autophagy is triggered by aggresome formation.
The autophagy inhibitor CQ potentiates chemotherapeutic
drug-induced apoptosis in lymphoma cells [45]. Inhibition of
autophagy by CQ alone prevents lymphomagenesis in murine
models [22]. We reasoned that I-kBa may be selectively degraded
by autophagy after recruited by p62. The autophagy inhibitor CQ
alone induced accumulation of ubiquitinated proteins, including I-
kBa. However, phosphorylated I-kBa was not significantly up-
regulated by CQ, indicating that CQ does not have effects
upstream of I-kBa phosphorylation. In the presence of bortezo-
mib, CQ prevented bortezomib-induced I-kBa degradation but
not I-kBa phosphorylation.
Using the ABC-DLBCL cell line Su-DHL8, we confirmed that
constitutivelyactivatednuclearNF-kB wasdetectedinun-stimulated
cells. Bortezomib-induced I-kBa degradation decreased its complex
formation with NF-kB and increased NF-kB nuclear translocation
and therefore its DNA binding activity. Blocking autophagy by CQ
sustained the levels of I-kBa protein and its binding to NF-kBa n d
inhibited bortezomib-induced NF-kB activation. As a result of NF-
kB activation, the increased transcriptional activity leads to up-
regulation of anti-apoptotic proteins. This may induce lymphoma
cells resistant to further treatment.
Inhibition of autophagy by CQ greatly sensitized DLBCL cells
to proteasome inhibitor-induced cell death, in keeping with results
in colon and ovarian cancer cells [13]. Interestingly, the most
resistant cell line Su-DHL10 which lacks Bax/Bak proteins [23],
underwent 60% cell death in response to the combined treatment
with both CQ and bortezomib (at 20 nM), indicating that blocking
both autophagy and proteasome degradation is a potent
therapeutic strategy to kill apoptosis-resistant lymphoma cells.
Although CQ sensitized DLBCL cells to proteasome inhibitor-
mediated cell death, the differential sensitivities of these DLBCL
cells to proteasome inhibitor was still persistent in the presence of
CQ, suggesting that CQ and bortezomib-induced cell death is
mitochondria-dependent.
In summary, here we report, for the first time, that bortezomib-
induced I-kBa degradation in DLBCL cells may be due to
activated autophagy. Autophagy plays a protective role in
proteasome inhibitor-induced cell death by eliminating cytotoxic
ubiquitinated proteins. It is well known that unbalanced
expression of BCL-2 family proteins confers differential sensitiv-
ities of cancer cells to chemotherapeutic drugs, including
bortezomib. Autophagy is another resistant factor which dimin-
ishes therapeutic effect in both sensitive and resistant lymphoma
cells. Elimination of I-kBa by autophagy induces NF-kB activation
and promotes cell survival. We therefore propose that blocking
proteasome and autophagy simultaneously can overcome resis-
tance of DLBCL cells to bortezomib-induced cell death.
Supporting Information
Figure S1 Daunorubicin uptake. Cells in culture medium
were subjected to the flow cytometry and the base line of the red
fluorescence was obtained by monitoring unstained cells for a few
seconds. After adding 100 mg/ml daunorubincin, the red fluores-
cent intensity was continuously monitored for 102 seconds on the
FL3-H channel.
(TIF)
cleaved PARP. (D) Cell death in primary FL and DLBCL cells. Primary cells from liquid nitrogen were cultured in fresh medium for 3 hours. Cells were
pre-treated with 30 mM CQ for 1 hour and then 20 nM bortezomib for 24 hours. Cell death was determined by flow cytometry. The significantly
increased killing was analyzed by t-test.
doi:10.1371/journal.pone.0032584.g007
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e32584Figure S2 Correlation of bortezomib-induced accumu-
lation of LC3-II and poly-ubiquitin. The levels of accumu-
lated poly-ubiquitin and LC3-II were analyzed by densitometry
and calculated as ratio of Ub/actin and LC3-II/actin, respectively.
Correlation between two levels of two proteins was analyzed by
Correlation (Prism).
(TIF)
Figure S3 Bortezomib and CQ induced co-localization
and aggregation of p62 and ubiquitin. Su-DHL10 cells were
treated with 10 nM Bortezomib or/and 50 mM CQ for 24 hours.
After fix/permeabilization, cells on slides were co-stained with a
polyclonal anti-p62 antibody (green) and a monoclonal anti-
ubiquitin antibody (red).
(TIF)
Figure S4 Bortezomib and CQ induced co-localization
and aggregation of p62 and LC3. Su-DHL10 cells were
treated with 10 nM Bortezomib, or/and 50 mM CQ for 24 hours.
After fix/permeabilization, cells on slides were co-stained with a
polyclonal anti-LC3B antibody (green) and a monoclonal anti-p62
antibody (red).
(TIF)
Figure S5 Co-localization of p62 and I-kBa. Su-DHL8 cells
were pre-incubated with or without 50 mM CQ for 1 hour and
then treated with 20 nM bortezomib for 24 hours. Cells on slides
were co-stained with polyclonal anti-I-kBa antibody (1:20) and
monoclonal anti-p62 antibody (1:20) and then probed with Alexa
Fluor anti-mouse IgG 546 (1:50 dilution) and anti-rabbit IgG-488
(1:100 dilution). Arrows indicate p62-I-kBa aggregates.
(TIF)
Figure S6 Expression of MCL-1, Bcl-XL and Bcl-2 in the
absence of treatment. Su-DHL8 cells were cultured up to
18 hours. Polyclonal anti-Mcl-1 (1:1000) and Bcl-XL (1:200)
antibodies, and monoclonal anti-Bcl-2 antibody (1:200) were used
for Western blotting.
(TIF)
Figure S7 CQ induced cell death. Cells were treated with
50 mM CQ for 24 hours. Cells were stained with PI and then cell
death was accessed by flow cytometry. Data presented are mean 6
SD from 3 independent experiments.
(TIF)
Figure S8 Effect of CQ on bortezomib-induced caspase
activation. Cells were pre-treated with 50 mM CQ for 1 hour
and then treated with bortezomib for 16 to 24 hours. Data are
mean 6 SD from 3 independent experiments.
(TIF)
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